Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01357655 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT01357655 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 70 participants.
The verdict
NCT01357655, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of the study is to compare response rates in newly diagnosed Chronic Phase (CP) CML subjects treated with dasatinib plus BMS-833923 versus dasatinib alone.
Interventions
- DRUG Dasatinib
- DRUG BMS-833923
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01357655
The ClinicalTrials.gov registry entry for NCT01357655 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dasatinib is the first listed.
NCT01357655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01357655 about?
NCT01357655 is a clinical study titled "Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)". The purpose of the study is to compare response rates in newly diagnosed Chronic Phase (CP) CML subjects treated with dasatinib plus BMS-833923 versus dasatinib alone.
What is the current status of trial NCT01357655?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2011-09. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01357655?
The interventions under investigation include: Dasatinib (DRUG), BMS-833923 (DRUG).
Who is sponsoring clinical trial NCT01357655?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.